Comparative analysis of prognostic factors in men undergoing radical prostatectomy for adenocarcinoma of the prostate, including DNA ploidy, surgical tumor stage, prostatic specific antigen, Gleason grade, and age

Prostate

Volumn 29, Issue 1, 1996, Pages 46-50

  Shockley, Kenneth F ^a   Maatman, Thomas J ^a   Carothers, George C ^a   Warzynski, Michael J ^b  

^a Metro Health Hospital   (United States)

^b Ferguson Hospital   (United States)

Author keywords

DNA ploidy; Gleason grade; prostatic specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PELVIS LYMPHADENECTOMY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA; AGE FACTORS; AGED; DNA, NEOPLASM; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PLOIDIES; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 0029891951     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199607)29:1<46::AID-PROS7>3.0.CO;2-G     Document Type: Article

References (25)

1. Ring K, Karp F, Olsson C, O'Toole K, Bixon R, Benson M: Flow cytometric analysis of localized adenocarcinoma of the prostate: The use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy. Prostate 17:155-164, 1990.
2. Peters-Gee J: An update on the role of ploidy in prostate carcinoma. Henry Ford Hosp Med J 40:99-102, 1992.
3. Deitch A, deVere White R: Flow cytometry as a predictive modality in prostate cancer. Hum Pathol 23:352-359, 1992.
4. Tribukait B, Ronstrom I, Esposti PL: Quantitative and qualitative aspects of flow DNA measurements related to the cytologic grade in prostatic carcinoma. Anal Quant Cytol 5:107-111, 1983.
5. Montgomery BT, Nativ O, Blute ML, Farrow GM, Myers RP, Zincke H, Therneau TM, Lieber MM: Stage B prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis. Arch Surg 125:327-331, 1992.
6. Nativ O, Winkler HZ, Raz Y, Therneau TM, Farrow GM, Myers RP, Zincke H, Lieber MM: Stage C prostate adenocarcinoma: Flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc 64:911-919, 1989.
7. Winkler HZ, Rainwater IM, Myers RP, Farrow GM, Therneau TM, Zinke H, Lieber MD: Stage D-1 prostatic adenocarcinoma: Significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63:103-112, 1988.
8. Tribukait B: Rapid flow cytometry of prostatic fine needle aspiration biopsies. In Karr JP, Coffey DE, Gardner W Jr (eds): "Prognostic Cytometry and Cytoflotometry of Prostate Cancer." New York: Elsevier Science Publishing Company, 1988, 236.
9. Bocking A, Chatelain R, Orthen V, Gien G, Kalckreuth Gv, Jocham B, Wohltmann D: DNA grading of prostatic carcinoma: Prognostic validity and and reproducibility. Anticancer Res 8:129-135, 1988.
10. Stephenson RA, James BC, Gay H, Fair WR, Whitmore WF Jr, Melamed MR: Flow cytometry of prostate cancer: Relationship of DNA content to survival. Cancer Res 47:2504-2507, 1987.
11. Lee SE, Currin SM, Paulson DF, Walther PJ: Flow cytometric determination of ploidy in prostatic adenocarcinoma: A comparison with seminal vesicle involvement and histopathological grading as predicter of clinical recurrence. J Urol 140:769-774, 1988.
12. Fordham MVP, Burdge AH, Matthews J, Williams G, Cooke T: Prostatic carcinoma cell content DNA measured by flow cytometry and its relation to clinical outcome. Br J Surg 72:400-403, 1986.
13. Lieber M, Cheng W: The role of nuclear DNA ploidy in the prognosis and management of patients with prostate cancer. Compr Ther 17:26-32, 1991.
14. Nativ O, Myers R, Farrow G, Therneau T, Zincke H, Lieber M: Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma. J Urol 144:303-306, 1990.
15. Gleason D, Mellinger G, Veterans Administration Cooperative Urological Research Group: Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64, 1974.
16. Gleason D: Histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum M (ed): "Urologic Pathology: The Prostate." Philadelphia: Lea and Febiger, 1977.
17. Hedley D, Friedlander M, Taylor I, Rugg C, Musgrove E: A method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335, 1983.
18. Hiddemann W, Schumann J, Andreeff M, Barlogie B, Herman C, Leif R, Mayall B, Murphy R, Sandberg A: Convention on nomenclature for DNA cytometry. Cytometry 5:445-446, 1984.
19. Badalament R, O'Toole R, Young D, Drago J: DNA ploidy and prostate specific antigen as prognostic factors in clinically resectable prostate cancer. Cancer 67: 3014-3023, 1991.
20. McNeal J, Kindrachuk R, Fuad F, Bostwick D, Redwine E, Stamey T: Patterns of progression in prostate cancer. Lancet 1:60-63, 1986.
21. Stamey T, Yang N, Hay R, McNeal J, Freiha F, Redwine E: Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909-916, 1987.
22. Stamey T, Kabalin J: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: I. Untreated patients. J Urol 14:1070-1075, 1989.
23. Stamey T, Johnston I, McNeal J, Kabalin J, Freiha F, Redwine E, Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol 141:1076-1083, 1989.
24. Shankey TV, Kallionieme OP, Koslowski J, Lieber M, Mayall B, Miller G, Smith G: Consensus review of the clinical utility of DNA content cytometry in prostate cancer. Cytometry 14:497-500, 1993.
25. Badalament R, Drago J: Prostate Cancer. Dis Mon 37: 199-268, 1991.